RxDoctor Payments Data

Raman Rao, MD

Nephrology · Indianapolis, INNPI 1538154406

Payments from drug & device makers

$1,360in general payments, 2019–2025

Across 16 payments — averaging $84.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$478
  • Fresenius USA Marketing, Inc.$193
  • Medtronic$187
  • Vifor Pharma, Inc.$125
  • Nxstage Medical, Inc.$125
  • Boehringer Ingelheim$122
  • plus $131 from 2 others

What the payments were for

  • Food & beverage$1,33298%
  • Education$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,360 in reported general payments places this provider in the 55th percentile of 238 nephrology providers in Indiana.

See all nephrology providers in Indiana

Medicare billing

Part B allowed, 2024
$135,813
Medicare patients
337
Services billed
1,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide14$56,768
AuryxiaFerric Citrate12$37,832
FarxigaDapagliflozin Propanediol47$32,220
JardianceEmpagliflozin38$31,573
VeltassaPatiromer Calcium Sorbitex17$10,316
Lanthanum Carbonate14$10,291
LokelmaSodium Zirconium Cyclosilicate13$9,293
Sevelamer Carbonate39$5,495
Potassium Citrate ErPotassium Citrate20$3,223
Amlodipine Besylate213$1,073
Calcitriol65$830
Losartan Potassium85$650
Potassium Chloride22$582
Torsemide34$530
Nifedipine ErNifedipine28$365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$193$56,76814 claims
AstraZenecaFarxiga, Lokelma$478$41,51360 claims
Boehringer IngelheimJardiance$122$31,57338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 238 nephrology providers in Indiana.

Other nephrology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →